UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000029210 |
|---|---|
| Receipt number | R000033382 |
| Scientific Title | A verification study for improving the quality of sleep by Lactobacillus brevis SBC8803 (SBL88TM) intake: A randomized double-blind, parallel-group, placebo-controlled study |
| Date of disclosure of the study information | 2017/09/20 |
| Last modified on | 2018/04/24 16:56:04 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A verification study for improving the quality of sleep by Lactobacillus brevis SBC8803 (SBL88TM) intake: A randomized double-blind, parallel-group, placebo-controlled study
Acronym
A study for improving the quality of sleep by lactic acid bacteria SBL88TM intake
Scientific Title
A verification study for improving the quality of sleep by Lactobacillus brevis SBC8803 (SBL88TM) intake: A randomized double-blind, parallel-group, placebo-controlled study
Scientific Title:Acronym
A study for improving the quality of sleep by lactic acid bacteria SBL88TM intake
Region
| Japan |
Condition
Condition
Healthy Japanese adults
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To investigate the effect of Lactobacillus brevis SBC8803 (SBL88TM) intake on quality of sleep.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
1. OSA sleep inventory MA version
*Fill it in immediately after waking up at home on the examination day and two days before
Key secondary outcomes
1. Sleep test (Sleep Scan)
2. Athens Insomnia Scale (AIS)
3. Japanese version of Epworth Sleepiness Scale (JESS)
4. Beck Depression Inventory
5. Visual Analogue Scale (VAS) of subjective symptoms
*1 Perform it at subject's home 1 week before screening and examination and during the test period
*2-5 Assess these at 0 and 4 weeks after consuming
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
NO
Dynamic allocation
YES
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
No need to know
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Duration: 4weeks
Test materials: Lactobacillus brevis SBC8803 (SBL88TM) sterilized lactic acid bacterial cells 25 mg (2.5 x 1010cells)
Dose: Take a tablet once a day
Administration: Take a tablet at optional timing.
*If you forget to take the test food, take it as soon as you remember within the day.
Interventions/Control_2
Duration: 4 weeks
Test materials: Placebo
Dose: Take a tablet once a day
Administration: Take a tablet at optional timing.
*If you forget to take the test food, take it as soon as you remember within the day.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Healthy Japanese adults
2. Subjects who feel quality of sleep dissatisfaction
3. Subjects who are judged as eligible to participate in the study by the principal investigator
4. Subjects who are considered as appropriate for the study by the principal investigator based on the score of Beck Depression Inventory
5. Among the subjects who passed 3. and 4., subjects who have a relatively lower score of OSA sleep inventory MA version at screening and examination before ingestion
Key exclusion criteria
1. At least one previous medical history or under the treatment of malignant tumor, heart failure or myocardial infarction
2. Currently under the treatment for either cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, sleep apnea syndrome, or other chronic diseases
3. Subjects who use or take "Foods for Specified Health Uses" and "Foods with Functional Claims" in daily
4. Currently taking medicines (include herbal medicines) and supplements
5. Subjects who are allergic to medicines and/or the test food related products
6. Subjects who are pregnant, breast-feeding, and plan to become a pregnant
7. Subjects who live with their infants less than 1 year old
8. Subjects who co-sleep with their children (1 to 6 years old)
9. Subjects who live with requiring long-term care persons
10. Subjects who share the bed with more than one person
11. Subjects who work late-night shift and the life-styles are irregular
12. Subjects whose body mass index (BMI) is 25 kg/m2 or more
13. Subjects who wake up for urination 3 times or more during nocturnal sleep
14. Subjects whose dinner time is extremely irregular
15. Subjects who are troubled with pollen allergy or asthma
16. Subjects who drink alcohol heavily
17. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial
18. Subjects who are judged as ineligible to participate in the study by the principal investigator
Target sample size
200
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Kazuo YAMAMOTO |
Organization
ORTHOMEDICO Inc.
Division name
CEO
Zip code
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL
03-3818-0610
kazu@orthomedico.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Naoko SUZUKI |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
ORTHOMEDICO Inc.
Institute
Department
Personal name
Funding Source
Organization
SAPPORO HOLDINGS LTD.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Medical Corporation Seishinkai, Takara Clinic
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2017 | Year | 09 | Month | 20 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 09 | Month | 11 | Day |
Date of IRB
Anticipated trial start date
| 2017 | Year | 09 | Month | 21 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2017 | Year | 09 | Month | 20 | Day |
Last modified on
| 2018 | Year | 04 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033382
